Automated deep brain stimulation programming with safety constraints for tremor suppression in patients with Parkinson’s Disease and essential tremor

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Automated deep brain stimulation programming with safety constraints for tremor suppression in patients with Parkinson's Disease and essential tremor August 3, 2022 J Neural Eng. 2022 Aug 3. doi: 10.1088/1741-2552/ac86a2. Online ahead of print.ABSTRACTOBJECTIVES: Deep brain stimulation programming for movement disorders requires systematic fine tuning of stimulation parameters to ameliorate tremor and other symptoms while avoiding side effects. DBS programming can be a time-consuming process and requires clinical expertise to assess response to DBS to optimize therapy for each patient. In this…
• Automated deep brain stimulation programming with safety constraints for tremor suppression in patients with Parkinson's Disease and essential tremor August 3, 2022 J Neural Eng. 2022 Aug 3. doi: 10.1088/1741-2552/ac86a2. Online ahead of print.ABSTRACTOBJECTIVES: Deep brain stimulation programming for movement disorders requires systematic fine tuning of stimulation parameters to ameliorate tremor and other symptoms while avoiding side effects. DBS programming can be a time-consuming process and requires clinical expertise to assess response to DBS to optimize therapy for each patient. In this…
• Automated deep brain stimulation programming with safety constraints for tremor suppression in patients with Parkinson's Disease and essential tremor August 3, 2022 J Neural Eng. 2022 Aug 3. doi: 10.1088/1741-2552/ac86a2. Online ahead of print.ABSTRACTOBJECTIVES: Deep brain stimulation programming for movement disorders requires systematic fine tuning of stimulation parameters to ameliorate tremor and other symptoms while avoiding side effects. DBS programming can be a time-consuming process and requires clinical expertise to assess response to DBS to optimize therapy for each patient. In this…
• Automated deep brain stimulation programming with safety constraints for tremor suppression in patients with Parkinson's Disease and essential tremor August 3, 2022 J Neural Eng. 2022 Aug 3. doi: 10.1088/1741-2552/ac86a2. Online ahead of print.ABSTRACTOBJECTIVES: Deep brain stimulation programming for movement disorders requires systematic fine tuning of stimulation parameters to ameliorate tremor and other symptoms while avoiding side effects. DBS programming can be a time-consuming process and requires clinical expertise to assess response to DBS to optimize therapy for each patient. In this…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Speech, Voice & Parkinson’s Q&A with John Dean January 28, 2021 We recently hosted a webinar with speech-language pathologist John Dean. You can get access to the recording here. We received so many questions during the session that we weren’t able to answer them all; so, John was kind enough to do some written Q&A for us. “When is a good time to start speech therapy?” It’s much better to maintain…
• Monthly Research Review – December 2021 December 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• 'Sunday Morning Futures' on Biden's mental capacity, Jill Biden comparing Latinos to tacos August 1, 2022 This is a rush transcript from "Sunday Morning Futures" July 17, 2022. This copy may not be in its final form and may be updated.MARIA BARTIROMO, FOX NEWS ANCHOR: Good Sunday morning, everyone. Welcome to "Sunday Morning Futures." Thanks so much for joining us. I'm Maria Bartiromo. Today: weakness on the world stage. President Biden coming home from the Middle East…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• EJS-ACT PD June 26, 2021 # # # # This week an announcement was made regarding The Edmond J. Safra Accelerating Clinical Treatments for Parkinson’s Disease (EJS-ACT PD) Initiative. It is hoping to revolutionise the way clinical trials for potentially disease-modifying drugs for Parkinson’s are conducted. The project is focused on the setting up a multi-arm, multi-stage (MAMS) platform for evaluating new therapies for PD.…
• Shining a light on Parkinson’s November 7, 2019   NOTE: The information in today’s post should not be considered an endorsement of PhotoPharmics or the treatment they are proposing. The author of this blog has had no communication with the company. The information in this post is provided because the author has been asked by readers to discuss it. In October 2018, at the annual International Movement Disorders…
• Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
• Isradipine: Posthoc analysis March 8, 2021 # # # # Last year the results of the large STEADY-PD study were published. The investigators behind the Phase III clinical trial reported that the experimental treatment being tested had no effect on the progression of Parkinson’s in recently diagnosed individuals. The treatment being evaluated was a calcium channel blocker called isradipine – it is used for treating high…
• Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
• Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
• Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
• The “What would I do” post? Part 2 January 22, 2022 # # # # I am very regularly asked “what would you do if you were diagnosed with Parkinson’s tomorrow?” As a research scientist I don’t really feel comfortable answering it, but I can see how it is a fair question. I have previously attempted to address it (Click here to read that post), and I point folks who do…
• Does immunotherapy need therapy? June 12, 2021 # # # # Over the last decade, a large number of clinical trials involving immunotherapy have been conducted in the field of Alzheimer’s research. The overall success rate of these studies has not been encouraging. Immunotherapy involves artificially boosting the immune system so that it targets of particular pathogen – like a rogue protein in the case of Alzheimer’s…